12 Sept 2017
The administration of abaloparatide (Tymlos) for 18 months followed by alendronate (Fosamax) for 2 years was associated with dramatic reductions in fracture risk among postmenopausal women, according to research presented at the American Society for Bone and Mineral Research annual meeting.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024